Header Logo

Connection

CHRISTIE BALLANTYNE to Coronary Disease

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Coronary Disease.
CHRISTIE BALLANTYNE
Connection Strength
9.187
Coronary Disease
  1. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.680
  2. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
    View in: PubMed
    Score: 0.496
  3. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.347
  4. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.339
  5. The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2012 May; 222(1):135-7.
    View in: PubMed
    Score: 0.301
  6. Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
    View in: PubMed
    Score: 0.297
  7. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J. 2012 Jan; 33(2):183-90.
    View in: PubMed
    Score: 0.287
  8. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.
    View in: PubMed
    Score: 0.202
  9. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
    View in: PubMed
    Score: 0.188
  10. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005 Jan; 5(1):9-14.
    View in: PubMed
    Score: 0.184
  11. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004 Nov 15; 94(10):1249-54.
    View in: PubMed
    Score: 0.182
  12. A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure. ESC Heart Fail. 2024 Apr; 11(2):1086-1096.
    View in: PubMed
    Score: 0.172
  13. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004 Jan; 18(1):67-75.
    View in: PubMed
    Score: 0.172
  14. MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study. Circ Heart Fail. 2023 11; 16(11):e010849.
    View in: PubMed
    Score: 0.169
  15. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One. 2023; 18(6):e0285259.
    View in: PubMed
    Score: 0.165
  16. Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease. Circulation. 2023 05 16; 147(20):1556-1559.
    View in: PubMed
    Score: 0.164
  17. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
    View in: PubMed
    Score: 0.164
  18. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
    View in: PubMed
    Score: 0.149
  19. Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study. JAMA Cardiol. 2021 01 01; 6(1):79-86.
    View in: PubMed
    Score: 0.139
  20. Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
    View in: PubMed
    Score: 0.139
  21. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
    View in: PubMed
    Score: 0.136
  22. Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Curr Atheroscler Rep. 2000 Jul; 2(4):281-3.
    View in: PubMed
    Score: 0.135
  23. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.132
  24. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
    View in: PubMed
    Score: 0.130
  25. Metabolomic Pattern Predicts Incident Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2019 07; 39(7):1475-1482.
    View in: PubMed
    Score: 0.125
  26. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998 Nov 05; 82(9A):3Q-12Q.
    View in: PubMed
    Score: 0.120
  27. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 1997 Dec; 8(6):354-61.
    View in: PubMed
    Score: 0.113
  28. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
    View in: PubMed
    Score: 0.110
  29. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017 07; 5(7):534-543.
    View in: PubMed
    Score: 0.109
  30. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.107
  31. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
    View in: PubMed
    Score: 0.106
  32. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
    View in: PubMed
    Score: 0.105
  33. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiol. 2016 08 01; 1(5):519-28.
    View in: PubMed
    Score: 0.103
  34. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.103
  35. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.100
  36. The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. Am J Epidemiol. 2016 Mar 01; 183(5):452-61.
    View in: PubMed
    Score: 0.099
  37. Increased expression of ICAM-1 in a case of accelerated coronary artery disease after heart transplantation. Tex Heart Inst J. 1996; 23(4):293-5.
    View in: PubMed
    Score: 0.099
  38. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.096
  39. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
    View in: PubMed
    Score: 0.096
  40. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014 Nov 27; 371(22):2072-82.
    View in: PubMed
    Score: 0.091
  41. Key references on transplant coronary artery disease. Circulation. 1994 Jul; 90(1):632-5.
    View in: PubMed
    Score: 0.089
  42. APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. Genetics. 2013 Dec; 195(4):1397-405.
    View in: PubMed
    Score: 0.084
  43. Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
    View in: PubMed
    Score: 0.084
  44. The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol. 2013 Aug 01; 178(3):401-9.
    View in: PubMed
    Score: 0.083
  45. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
    View in: PubMed
    Score: 0.079
  46. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.076
  47. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31; 59(5):484-9.
    View in: PubMed
    Score: 0.075
  48. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.074
  49. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
    View in: PubMed
    Score: 0.074
  50. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012 Jan; 33(2):238-51.
    View in: PubMed
    Score: 0.074
  51. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
    View in: PubMed
    Score: 0.071
  52. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.071
  53. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
    View in: PubMed
    Score: 0.071
  54. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.
    View in: PubMed
    Score: 0.067
  55. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009 Jul; 102(1):179-80.
    View in: PubMed
    Score: 0.063
  56. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009 Jun; 2(3):279-85.
    View in: PubMed
    Score: 0.062
  57. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.
    View in: PubMed
    Score: 0.059
  58. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008 Mar; 155(3):541-6.
    View in: PubMed
    Score: 0.056
  59. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
    View in: PubMed
    Score: 0.051
  60. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol. 2006 Aug 15; 164(4):342-8.
    View in: PubMed
    Score: 0.051
  61. Lipids and CVD management: towards a global consensus. Eur Heart J. 2005 Nov; 26(21):2224-31.
    View in: PubMed
    Score: 0.048
  62. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003 Apr 08; 107(13):1729-32.
    View in: PubMed
    Score: 0.041
  63. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.041
  64. Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract Suppl. 2002 Jul; (130):22-6.
    View in: PubMed
    Score: 0.039
  65. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04; 104(10):1108-13.
    View in: PubMed
    Score: 0.037
  66. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021 04; 69(4):986-994.
    View in: PubMed
    Score: 0.034
  67. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12; 158(18):1977-89.
    View in: PubMed
    Score: 0.030
  68. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.028
  69. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
    View in: PubMed
    Score: 0.028
  70. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol. 1997 Mar; 12(2):153-60.
    View in: PubMed
    Score: 0.027
  71. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.026
  72. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
    View in: PubMed
    Score: 0.025
  73. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.023
  74. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013 Jun; 62(6):2116-21.
    View in: PubMed
    Score: 0.020
  75. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc. 1993 Feb; 25(1 Pt 1):233-6.
    View in: PubMed
    Score: 0.020
  76. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
    View in: PubMed
    Score: 0.020
  77. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov-Dec; 6(6):565-72.
    View in: PubMed
    Score: 0.019
  78. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012 May; 59(5):653-62.
    View in: PubMed
    Score: 0.019
  79. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8.
    View in: PubMed
    Score: 0.018
  80. Detection of transplant arteriopathy: does exercise thallium scintigraphy improve noninvasive diagnostic capabilities? Transplant Proc. 1991 Feb; 23(1 Pt 2):1189-92.
    View in: PubMed
    Score: 0.018
  81. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991 Feb 01; 67(4):243-7.
    View in: PubMed
    Score: 0.018
  82. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.016
  83. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
    View in: PubMed
    Score: 0.014
  84. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008 Feb; 196(2):926-30.
    View in: PubMed
    Score: 0.013
  85. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991 Oct; 18(4):926-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.